All the following are true regarding emtricitabine, except
All the following are true regarding efavirenz, except
All the following are true regarding ritonavir, except
All the following are true regarding enfuvirtide, except
All the following are true regarding dolutegravir, except
All the following are true regarding maraviroc, except
All the following are true regarding cobicistat, except
All the following are true regarding antiretroviral therapy, except
All the following are true regarding post-exposure prophylaxis (PEP) of HIV, except
All the following are true regarding prophylactic treatment of infants born to HIV-infected mothers, except